Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality
Overview
Affiliations
Cancer and diabetes are amongst the leading causes of deaths worldwide. There is an alarming rise in cancer incidences and mortality, with approximately 18.1 million new cases and 9.6 million deaths in 2018. A major contributory but neglected factor for risk of neoplastic transformation is hyperglycemia. Epidemiologically too, lifestyle patterns resulting in high blood glucose level, with or without the role of insulin, are more often correlated with cancer risk, progression, and mortality. The two conditions recurrently exist in comorbidity, and their interplay has rendered treatment regimens more challenging by restricting the choice of drugs, affecting surgical consequences, and having associated fatal complications. Limited comprehensive literature is available on their correlation, and a lack of clarity in understanding in such comorbid conditions contributes to higher mortality rates. Hence, a critical analysis of the elements responsible for enhanced mortality due to hyperglycemia-cancer concomitance is warranted. Given the lifestyle changes in the human population, increasing metabolic disorders, and glucose addiction of cancer cells, hyperglycemia related complications in cancer underline the necessity for further in-depth investigations. This review, therefore, attempts to shed light upon hyperglycemia associated factors in the risk, progression, mortality, and treatment of cancer to highlight important mechanisms and potential therapeutic targets.
Modern-Day Management of the Dysglycemic Continuum: An Expert Viewpoint from the Arabian Gulf.
Alessa T, Al Awadi F, Al Kaabi J, Al Mamari A, Al Ozairi E, Alromaihi D Diabetes Metab Syndr Obes. 2024; 17:4791-4802.
PMID: 39712240 PMC: 11662629. DOI: 10.2147/DMSO.S491591.
A novel approach to regulate glucose uptake in an anaplastic thyroid cancer cell line.
Heydarzadeh S, Moshtaghie A, Daneshpour M, Hedayati M Endocr Connect. 2024; .
PMID: 39555605 PMC: 11728915. DOI: 10.1530/EC-24-0336.
Asiri A, Al Qarni A, Bakillah A Diagnostics (Basel). 2024; 14(19).
PMID: 39410536 PMC: 11475808. DOI: 10.3390/diagnostics14192132.
Effects of T2DM on cancer progression: pivotal precipitating factors and underlying mechanisms.
Zhang Y, Li Y, Xue C, Li S, Gao Z, Qin K Front Endocrinol (Lausanne). 2024; 15:1396022.
PMID: 39290325 PMC: 11405243. DOI: 10.3389/fendo.2024.1396022.
Particle Beam Radiobiology Status and Challenges: A PTCOG Radiobiology Subcommittee Report.
Ahmad R, Barcellini A, Baumann K, Benje M, Bender T, Bragado P Int J Part Ther. 2024; 13:100626.
PMID: 39258166 PMC: 11386331. DOI: 10.1016/j.ijpt.2024.100626.